Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1405 participants.

Also called NCT01422876

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,405 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01422876
  • EudraCT 2011-000383-10
Other papers using this trial's data
  • Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin Diabetes care, 2015-03 DOI, PubMed 25583754 PubMed links an erratum for this paper. Erratum: PMID 25998298
  • Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes Diabetes care, 2015-03 DOI, PubMed 25633662 PubMed links an erratum for this paper. Erratum: PMID 25998299
  • Safety and Tolerability of Combinations of Empagliflozin and Linagliptin in Patients with Type 2 Diabetes: Pooled Data from Two Randomized Controlled Trials Advances in therapy, 2018-07 DOI, PubMed 29949041, PMC11343821 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Brazil, Bulgaria, Canada, Colombia, Denmark, Estonia, Hungary, Italy, Lebanon, Malaysia, Mexico, Peru, Philippines, Poland, Romania, Russia, Spain, Sweden, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01422876. Randomized; double masking; primary purpose treatment. Start 2011-08 (registry gives no type); primary completion 2013-09 (actual). Results posted on 2015-04-02.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
high dose FDC
Intervention (Drug)
BI 10773 high dose
Intervention (Drug)
high dose FDC placebo
Intervention (Drug)
low dose FDC placebo
Intervention (Drug)
high dose FDC placebo
Intervention (Drug)
high dose FDC placebo
Intervention (Drug)
low dose FDC placebo
Intervention (Drug)
low dose FDC placebo
Intervention (Drug)
high dose BI 10773 placebo
Intervention (Drug)
low dose FDC
Intervention (Drug)
high dose FDC placebo
Intervention (Drug)
BI 10773 low dose
Intervention (Drug)
high dose BI 10773 placebo
Intervention (Drug)
high dose BI 10773 placebo
Intervention (Drug)
linagliptin
Intervention (Drug)
low dose FDC placebo
Intervention (Drug)
linagliptin placebo
Intervention (Drug)
BI 10773 low dose placebo
Intervention (Drug)
linagliptin placebo
Intervention (Drug)
low dose BI 10773 placebo
Intervention (Drug)
linagliptin placebo
Intervention (Drug)
high dose BI 10773 placebo
Intervention (Drug)
BI 10773 low dose placebo
Intervention (Drug)
low dose BI 10773 placebo
Intervention (Drug)
linagliptin placebo
Lead sponsor
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01422876
Content hash
167e2d188719d6353b5b778c02e038282dc9bdb33d6037f153690511e471bea6